Classifying mental disorders using traditional tools like the Diagnostic and Statistical Manual misses the vast differences in biomarkers that can exist in patients with the same diagnosis, which is why research is looking to biological measures and “biotypes” to provide more information, according to Godfrey Pearlson, MD, professor of psychiatry and neuroscience, Yale School of Medicine.
Classifying mental disorders using traditional tools like the Diagnostic and Statistical Manual (DSM) misses the vast differences in biomarkers that can exist in patients with the same diagnosis, which is why research is looking to biological measures and “biotypes” to provide more information, according to Godfrey Pearlson, MD, professor of psychiatry and neuroscience, Yale School of Medicine.
Transcript
How could biologic measures be used to create a new framework of psychiatric diseases?
So, if you just temporarily toss out conventional DSM-type traditional psychiatric measures and start from the bottom up, using only biology as a classifier, you end up with very, very different syndromes. For example in the B-SNIP project, looking at bipolar illness, schizoaffective disorder, and schizophrenia, when we took that approach to just removing DSM labels from patients with psychotic illnesses, putting them all into one huge group, trying to classify them from the bottom up using biology, we came up with 3 new typologies that we call biotypes.
Each biotype contains people with each of the 3 diagnoses, and they all look very similar symptomatically—they all have hallucinations and delusions and some mood symptoms—but from the point of view of biology they look completely different from each other, even in opposite directions. So some biological measure may be greatly increased above normal in one group, in one biotype, and way below normal in the other, but they, say, may be both containing people with schizophrenia, so you can imagine what would happen if you averaged across people who are way high and way low, you’d just be very confused, which is I think the way biology is at the moment.
So I think if you classify based on biology, which is sort of what RDoC [Research Domain Criteria] from NIMH is trying to do, you end up ahead on average, and more informed, with more facts than you had before.
Which biological measures hold the most promise as indicators for classifying these illnesses and why?
Yeah, well that’s the key question. We really don’t know the answer to that yet. We have a lot of measures, and most likely, I think, in the beginning, we’ll find fingerprints that identify new diseases, classified by biology, that are based on an agglomeration, a mixture of different kinds of biological indicators. I don’t think there’s any one that’s going to be key in the beginning, but it’ll be a mixture that leads to a fingerprint.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More